biotech / news / / The Manila Times
New company ("NewCo”) co-founded by Nxera with a syndicate of leading healthcare and life sciences-focused investment firms.
Nxera co-founded NewCo to advance a GPCR-targeted program discovered via NxWave™ technology.
KEY POINTS
- Nxera is eligible for up to US$275 million in milestone payments and retains tiered royalties.
- Nxera retains commercial rights in Japan and certain Asia-Pacific territories for the GPCR program.
- This is Nxera’s second asset spin-out, following a model previously validated by Orexia Therapeutics.
COMPANIES
Summarized by Newsio from The Manila Times. How we summarize →